The central claim of the review is that reactive oxygen species, long recognized as master regulators of cell fate, can kill a cell by disabling a specific lipid kinase that maintains endosomal identity. That kinase is the class III phosphatidylinositol 3-kinase, better known in the field as PIK3C3 or VPS34. VPS34 is responsible for generating phosphatidylinositol 3-phosphate, or PI3P, a signaling lipid that decorates early endosomes and recruits the effector proteins needed for vesicular trafficking, endosomal maturation, and autophagy initiation. According to the authors, when oxidative stress reaches a critical level, ROS oxidize and inactivate VPS34. The resulting depletion of PI3P strips endosomes of their molecular identity, disrupts the trafficking networks that depend on it, and sets in motion a cascade that ends with the accumulation of enlarged, dysfunctional vacuoles and progressive cellular collapse.

What makes triaptosis mechanistically distinctive is its stubborn persistence in the face of interventions that block every canonical death pathway. The review emphasizes that triaptosis proceeds even when caspases are inhibited, when necroptotic signaling is suppressed, and when lipid peroxidation is prevented. In other words, a cell undergoing triaptosis does not die because its executioner caspases have been activated, because its membrane lipids have been oxidized in the manner characteristic of ferroptosis, or because inflammatory necroptotic machinery has fired. Instead, the defining lesion is the ROS-driven failure of endosomal homeostasis. This pharmacological independence is precisely what elevates triaptosis from a curiosity to a candidate for a genuinely separate cell death program, and it offers researchers a new set of experimental handles for distinguishing it from apoptosis, ferroptosis, necroptosis, and pyroptosis in cultured cells and tissues.

The spatial logic of the pathway is central to the authors’ argument. Redox signaling, they stress, is not a uniform flood of oxidizing molecules but a spatially organized and context-dependent system in which specific organelles experience specific oxidative insults. Established ROS-regulated death pathways have largely been interpreted through mitochondrial dysfunction, lipid peroxidation, inflammatory signaling, and DNA damage, leaving the endosomal system underexplored as a primary target of oxidative killing. Triaptosis fills that gap by proposing that the endosome itself can be the decisive target. In this view, ROS-mediated cytotoxicity may arise through targeted organelle failure alongside mitochondrial dysfunction, lipid peroxidation, and nuclear damage, expanding the conceptual map of how oxidants decide whether a cell survives, adapts, or dies.

A key question for any proposed death pathway is what determines whether a given cell succumbs. For triaptosis, the review identifies the answer in the cell’s redox buffering capacity, the biochemical machinery that keeps reactive oxygen species in check. Two components loom largest. The first is glutathione, the abundant intracellular antioxidant that directly neutralizes oxidants and maintains protein thiols in their reduced state. The second is the KEAP1-NRF2 pathway, the master transcriptional circuit that senses electrophilic and oxidative stress and, in response, upregulates a broad program of antioxidant and detoxifying genes. Together, glutathione levels and KEAP1-NRF2 activity set the threshold at which VPS34 becomes oxidized and PI3P begins to disappear. Cells with robust buffering can tolerate oxidative insults that would push a poorly buffered neighbor over the edge into endosomal collapse.

This threshold concept has immediate implications for how scientists might study and manipulate the pathway. Because triaptosis depends on VPS34 oxidation rather than on any single downstream executioner, the susceptibility of a cell is essentially a function of how close its redox state sits to the point of kinase failure. Experimental manipulations that deplete glutathione, inhibit NRF2 signaling, or otherwise erode antioxidant defenses would be expected to lower the threshold, allowing oxidative stresses that are otherwise survivable to trigger PI3P loss and vacuolar catastrophe. Conversely, reinforcing antioxidant capacity should raise the threshold and protect cells. This framework turns triaptosis into a quantifiable phenomenon: rather than asking simply whether ROS are present, researchers can ask whether a cell’s buffering capacity has been pushed below the level needed to keep VPS34 functional.

The therapeutic implications, particularly in oncology, form one of the most provocative threads of the review. Cancer cells frequently live in a state of elevated basal oxidative stress, a consequence of oncogenic signaling, metabolic reprogramming, and rapid proliferation. To survive, they compensate by shoring up their antioxidant systems, often relying heavily on glutathione metabolism and NRF2-driven transcription. The authors argue that this adaptation places many tumors in a near-threshold redox state, poised perilously close to the point at which VPS34 oxidation and PI3P depletion begin. In such cells, a modest additional oxidative push, or a targeted erosion of glutathione buffering, could selectively tip the balance toward endosomal collapse while sparing normal cells that operate with a wider redox margin. Triaptosis thus offers a conceptual route to exploiting a well-known vulnerability of cancer cells through an organelle-specific mechanism that has not previously been targeted.

The review also situates triaptosis within the broader network of ROS-regulated cell death, drawing careful distinctions between the new pathway and its established relatives. Apoptosis is executed by caspases and characterized by nuclear fragmentation and membrane blebbing; ferroptosis depends on iron-catalyzed lipid peroxidation of cellular membranes; necroptosis and pyroptosis are lytic, inflammatory programs driven by dedicated signaling complexes. Triaptosis shares none of these execution mechanisms and is instead defined by the loss of PI3P-dependent endosomal identity and the accumulation of dysfunctional vacuoles. The authors integrate the pathway into the ROS-RCD network as a parallel branch rather than a variant of any existing program, suggesting that the cellular response to oxidative stress may branch at an early point: if mitochondria, membranes, and DNA hold, the endosomal system may nonetheless fail, and that failure alone can be lethal.

As a review article, the work synthesizes and interprets rather than reports a single decisive experiment, and the authors are careful to frame triaptosis as an emerging framework whose boundaries remain to be mapped. Open questions include precisely how ROS oxidize VPS34 in living cells, which cysteine residues or cofactors are most vulnerable, how quickly PI3P must be depleted before endosomal identity is irreversibly lost, and whether the enlarged vacuoles that characterize the pathway are cause or consequence of the final collapse. It will also fall to future work to identify biomarkers that distinguish triaptosis in pathological tissue and to develop pharmacological tools that modulate the pathway selectively. The study was supported by a grant from New York University Abu Dhabi, and the authors declare no competing interests.

Even with those caveats, the appearance of triaptosis in the cell death literature marks a notable conceptual shift. It relocates a decisive node of oxidative cell death from the power plants and archives of the cell to its logistics network, and it reframes redox toxicity as a matter of targeted organelle failure rather than indiscriminate damage. If subsequent experimental work confirms and refines the mechanism, triaptosis could reshape how researchers think about oxidative stress in cancer therapy, neurodegeneration, and inflammatory disease, and it may inspire a search for other organelle-centered death programs hiding in plain sight. For a field that has spent decades cataloguing the ways cells die, the message is that the map is still expanding, and that some of the most important territory may lie in the smallest of cellular compartments.

Subject of Research: An endosome-centered mechanism of ROS-regulated cell death involving oxidative inactivation of VPS34 and depletion of PI3P

Article Title: Triaptosis: an emerging endosome-centered mechanism of ROS-regulated cell death

Article References: Thayyullathil, F., Cheratta, A. R., & Galadari, S. (2026). Triaptosis: an emerging endosome-centered mechanism of ROS-regulated cell death. Cell Death Discovery. https://doi.org/10.1038/s41420-026-03368-5

Image Credits: AI Generated

DOI: 10.1038/s41420-026-03368-5

Keywords: triaptosis, cell death, reactive oxygen species, endosomes, VPS34, PI3P, oxidative stress, glutathione, KEAP1-NRF2, ferroptosis, apoptosis, cancer therapy

A team of French researchers has now built exactly that tool. Writing in PLOS Computational Biology, Chloé Weckel of the French National Research Institute for Agriculture, Food and the Environment and her colleagues, together with collaborators including Stefan Haar of the École Polytechnique and Romain Yvinec of INRAE, present a generic dynamic model of GPCR signaling that explicitly incorporates receptor trafficking: internalization from the plasma membrane, sorting inside endosomes, and recycling back to the surface. The work, published on September 29, 2026, is not merely another computational exercise. It is an attempt to make the spatial choreography of receptors a first-class citizen in theoretical models, rather than an afterthought, and then to test what that choreography actually contributes to a real hormonal response.

The central premise of the study is deceptively simple. If the kinetics and spatial localization of signaling determine how a cell responds to a ligand, then any model that ignores where the receptor is at a given moment is missing a critical variable. Receptors do not sit still. Ligand binding can trigger their internalization into endosomes, where they may continue to activate G proteins and other effectors, or they may be sorted for destruction. Many receptors are recycled back to the cell surface, replenishing the pool available for the next round of stimulation. Each of these steps has its own timescale, and each timescale feeds back into the shape of the signaling curve, how fast the response rises, how long it persists, and whether it is sustained or transient. The new model captures this interplay directly, allowing researchers to systematically characterize how endosomal dynamics and receptor recycling influence ligand-induced cellular responses.

What makes the approach powerful is its generality. Rather than hard-coding the behavior of one receptor, the authors constructed a framework in which trafficking and signaling compartmentalization are explicit, modular components. This means the same architecture can be adapted to different GPCRs by adjusting parameters, and, crucially, it means the model can be interrogated: which trafficking steps matter most for a given ligand, and under what conditions does endosomal signaling dominate over surface signaling? Such questions have real pharmacological weight. Two drugs that activate the same receptor with similar potency in a standard surface-based assay could produce very different cellular outcomes if one of them preferentially drives internalization or blocks recycling. A model that can distinguish these scenarios offers a far more refined instrument for characterizing ligands than conventional dose-response curves.

To prove the point, the team turned to a receptor with major biological and agricultural significance: the follicle-stimulating hormone receptor, or FSHR. FSH is the master regulator of reproductive function, driving follicle growth in the ovary and sperm production in the testis, and its receptor is a canonical GPCR whose signaling has been studied intensively. The researchers paired their model with high-throughput kinetic data on FSH-induced signaling, using a model selection strategy to determine which combinations of trafficking and signaling assumptions best explained the observed dynamics. This is where the study delivers its most striking surprise: although only a small fraction of FSH receptors is actually internalized, those few endosomal receptors generate a highly active signaling response inside the cell.

The implication of that finding is outsized. If a minority of internalized receptors can punch far above their numerical weight, then any drug or genetic perturbation that alters receptor trafficking, even modestly, could have dramatic consequences for the overall signaling output. A compound that speeds up internalization, slows recycling, or changes how receptors are sorted within endosomes would not merely shuffle receptors around; it would reshape the very profile of the cellular response. For reproductive medicine and livestock breeding, where FSHR ligands are used or studied therapeutically, this reframes how such molecules should be evaluated. A ligand’s pharmacological identity cannot be fully captured without knowing what it does to receptor traffic.

The study also speaks to a broader conceptual shift in cell biology. The emerging view of signaling holds that location is information: a receptor signaling from an endosome encounters a different set of effector molecules, scaffold proteins, and deactivating enzymes than it does at the plasma membrane, so the same receptor can produce qualitatively different downstream effects depending on where it is active. Endosomal signaling has been implicated in sustained responses such as the prolonged activity of certain receptors involved in neuronal function and metabolism. By building trafficking into a quantitative framework, the French team has provided a way to move this discussion from anecdote to arithmetic, converting a qualitative appreciation of spatial organization into testable, parameterized predictions.

Methodologically, the work sits at the intersection of dynamical systems modeling and high-throughput experimental biology. The model selection approach, in which competing mechanistic hypotheses are scored against kinetic data, allows the data themselves to adjudicate which trafficking behaviors are essential and which are dispensable for explaining the observed signaling. This discipline matters because GPCR systems are notoriously over-parameterized: with dozens of rate constants describing binding, internalization, degradation, recycling, and signaling at multiple locations, a model can easily become flexible enough to fit anything. By forcing the model to compete against real FSHR kinetics, the researchers ensured that the retained mechanisms, including the outsized contribution of endosomal signaling, earned their place in the explanation rather than being assumed from the outset.

The authors are careful to frame their contribution as generalizable. Beyond FSHR, the methodology offers a strategy for modeling trafficking dynamics across the GPCR superfamily, which includes receptors for neurotransmitters, hormones, sensory stimuli, and countless other ligands. Because the framework treats internalization, endosomal sorting, and recycling as explicit, tunable processes, it can in principle be calibrated to any receptor for which suitable kinetic data exist. That opens the door to a systematic, comparative pharmacology of trafficking: a future in which every ligand is characterized not only by how strongly it activates a receptor but by how it redistributes that receptor across the cell’s interior landscape.

For drug developers, the message is both a warning and an opportunity. The warning is that assays confined to the cell surface may systematically misjudge compounds whose most important effects occur inside endosomes, or whose toxicity and efficacy hinge on perturbing receptor recycling. The opportunity is that trafficking itself becomes a design target: molecules could be engineered to prolong or curtail endosomal signaling deliberately, tailoring not just the strength of a drug’s effect but its duration and spatial character. As the PLOS Computational Biology study makes clear, the journey of a receptor into the cell is not the end of its story. In many cases, it is where the real signaling begins, and understanding that journey quantitatively may prove as important to future pharmacology as the receptor itself.

Subject of Research: Spatiotemporal computational modeling of GPCR signaling, endosomal dynamics, and receptor recycling

Article Title: Spatiotemporal modeling of GPCR signaling: The role of endosomal dynamics and receptor recycling

Article References: Weckel, C., Gourdon, J., Darrigade, L., Jugnarain, V., Crépieux, P., Reiter, E., Jean-Alphonse, F., Haar, S., & Yvinec, R. (2026). Spatiotemporal modeling of GPCR signaling: The role of endosomal dynamics and receptor recycling. PLOS Computational Biology, 22(9), e1014790. https://doi.org/10.1371/journal.pcbi.1014790

Image Credits: AI Generated

DOI: 10.1371/journal.pcbi.1014790

Keywords: GPCR signaling, endosomes, receptor recycling, receptor trafficking, FSHR, computational biology, model selection, pharmacology, cell signaling, ligand characterization, PLOS Computational Biology, spatiotemporal modeling

The research, led by Ana Cristina Reguera and Rosalía Rodríguez-Rodríguez at the Universitat Internacional de Catalunya, together with colleagues in Spain, Austria, and the United Kingdom, focuses on an unusual phospholipid known as bis(monoacylglycero)phosphate, or BMP. Unlike most cellular lipids, BMP is not scattered across membranes; it is almost exclusively found in late endosomes, the acidic compartments where cellular cargo is sorted, degraded, and recycled. BMP is required for the formation of intraluminal vesicles, the small bubbles that carry cargo into the interior of these compartments, and it plays a central role in cholesterol handling and lysosomal function. Without adequate BMP, the late endosomal system essentially loses its operating fluid.

What has puzzled researchers is how neurons maintain the right amount of this specialized lipid. BMP is chemically unusual, resistant to many common phospholipases, but it does have one known executioner: an enzyme called ABHD6, alpha-beta hydrolase domain containing 6. ABHD6 can hydrolyze BMP, breaking it down. The new work shows that the activity of this hydrolase is not constant; it is tuned by the metabolic state of the cell, and the tuning knob is CPT1C, a brain-specific member of the carnitine palmitoyltransferase family that sits in the endoplasmic reticulum and is known to respond to nutrient and energy cues.

CPT1C is an intriguing protein in its own right. Unlike its relatives CPT1A and CPT1B, which drive fatty acid import into mitochondria, CPT1C has negligible transferase activity. Instead, it behaves as a lipid and energy sensor, accumulating in neurons during fasting and low-energy states and helping neurons adapt their metabolism accordingly. The new study reveals an unexpected downstream target for this sensor: by restraining ABHD6, CPT1C protects the BMP pool that late endosomes depend on. In other words, a protein long studied for its role in energy sensing turns out to be a critical regulator of the lipid composition of the degradative compartments themselves.

The experimental logic of the study is straightforward and compelling. When the researchers removed CPT1C from neurons, ABHD6 activity rose, intracellular BMP levels fell, and the endolysosomal system began to falter. The consequences were measurable at several points along the pathway. Endosomal maturation was impaired, meaning early endosomes failed to progress properly into functional late compartments. The release of extracellular vesicles, including exosomes, which bud from late endosomes and depend on intraluminal vesicle formation, was reduced. Lysosomes lost their normal acidity, and their proteolytic activity, the enzymatic digestion of cargo, declined. Each of these defects is consistent with a shortage of the BMP that late endosomes and lysosomes need to build and maintain their internal architecture.

Crucially, the team showed that the problem was not a failure to synthesize BMP but an acceleration of its destruction. When they acutely inhibited ABHD6 in CPT1C-deficient neurons, BMP levels recovered, and the endolysosomal defects were rescued. This pharmacological rescue is one of the strongest signals in the paper, because it establishes a clear causal chain: CPT1C loss elevates ABHD6 activity, elevated ABHD6 depletes BMP, and BMP depletion undermines endolysosomal function. Blocking the hydrolase reverses the cascade at its source.

The nutrient dimension of the story emerged when the researchers exposed cells and animals to lipid overload. In wild-type neurons and in the hypothalamus of mice fed excess fat, ABHD6 activity increased and BMP levels dropped, mirroring the phenotype seen in CPT1C-deficient cells. But there was a telling difference: CPT1C-deficient neurons and mice already displayed constitutively elevated ABHD6 activity, and when faced with additional lipid excess, they failed to adapt further. Their regulatory range was exhausted. This suggests that CPT1C does not merely set a baseline for BMP homeostasis; it provides the adaptive capacity that neurons need when the lipid environment changes, as it does in high-fat diets and obesity.

Why does this matter for whole-body metabolism? The hypothalamus is the command center that integrates hormonal and nutrient signals to regulate food intake, energy expenditure, and glucose homeostasis. If lipid overload degrades the endolysosomal health of hypothalamic neurons, it could compromise the very cells responsible for sensing metabolic state and orchestrating the response. Defective lysosomal acidification and proteolysis would impair the degradation of proteins and organelles, including through autophagy, while reduced exosome release could alter intercellular communication within hypothalamic circuits. The study does not claim to have demonstrated these downstream physiological effects, but it establishes the molecular lesion, BMP depletion through unrestrained ABHD6, that could plausibly feed into hypothalamic dysfunction in metabolic disease.

The findings also connect to a broader and rapidly growing literature on lysosomal lipids in neurobiology. BMP has attracted intense interest because it is the receptor for a family of DNAJ proteins that stimulate lysosomal activity, and because altered BMP metabolism has been implicated in neurodegenerative conditions in which lysosomal failure is a hallmark. Neurons are particularly vulnerable to lysosomal dysfunction because they are long-lived and cannot dilute accumulated damage by cell division. A pathway in which a nutrient sensor controls the abundance of the signature lipid of the degradative pathway therefore offers a direct mechanistic bridge between diet, neuronal metabolism, and cellular housekeeping.

Therapeutically, the study points to ABHD6 as a druggable node. Pharmacological ABHD6 inhibition restored BMP levels in CPT1C-deficient neurons, raising the possibility that modulating this hydrolase could protect endolysosomal function in settings of chronic lipid excess. ABHD6 inhibitors have already been explored in other contexts, including endocannabinoid signaling, which gives medicinal chemists a starting point. The authors caution, implicitly, that much remains to be worked out: how CPT1C physically restrains ABHD6, whether the axis operates in other neuronal populations, and whether restoring BMP in vivo can correct hypothalamic dysfunction in obesity models. But the identification of a nutrient-sensitive CPT1C-ABHD6 axis governing BMP homeostasis gives researchers a concrete molecular handle on a process that had been almost entirely opaque. It reframes CPT1C not just as a metabolic sensor at the endoplasmic reticulum but as a custodian of the neuronal recycling system, and it suggests that the road from a fatty diet to faulty cellular waste disposal in the brain may run through a single, targetable enzyme.

Subject of Research: Nutrient-sensitive regulation of BMP lipid homeostasis and endolysosomal function in hypothalamic neurons via the CPT1C-ABHD6 axis

Article Title: A nutrient-sensitive CPT1C-ABHD6 axis regulates BMP homeostasis and endolysosomal function in hypothalamic neurons

Article References: Reguera, A. C., Miralpeix, C., Bernard, M., Zagmutt, S., Bolaños-Hurtado, M., Palacín, C., Fuentes, A., Rodríguez-García, M., Fosch, A., Garcia-Chica, J., Barnadas-Rodríguez, R., Fawzy, N., Zimmermann, R., Eden, E., Casals, N., & Rodríguez-Rodríguez, R. (2026). A nutrient-sensitive CPT1C-ABHD6 axis regulates BMP homeostasis and endolysosomal function in hypothalamic neurons. Cellular and Molecular Life Sciences. https://doi.org/10.1007/s00018-026-06451-3

Image Credits: AI Generated

DOI: 10.1007/s00018-026-06451-3

Keywords: CPT1C, ABHD6, BMP, endolysosomal system, hypothalamus, neurons, lipid metabolism, lysosomes, nutrient sensing, exosomes, obesity, endosomes

Trypanosomatid flagellates such as Trypanosoma brucei and T. cruzi have long fascinated cell biologists because their endocytic traffic is confined to a single invagination of the plasma membrane called the flagellar pocket. This unusual geometry makes them powerful models for testing how universal the principles of membrane trafficking really are. Previous work had catalogued many components of clathrin-mediated endocytosis in these parasites, but the composition and evolutionary standing of their ESCRT machinery remained incompletely resolved. In animals and fungi, a subcomplex called ESCRT-0, built around the Vps27/Hrs and STAM proteins, recognises ubiquitylated substrates and hands them to the downstream complexes. Whether trypanosomes possess anything comparable has been an open question.

The team approached the problem from two directions: comparative genomics across the eukaryotic tree and experimental biochemistry in the parasite itself. Using hidden Markov model searches and reciprocal best BLAST analyses, they surveyed hundreds of genomes from every major eukaryotic supergroup for orthologs of candidate sorting proteins. In parallel, they engineered procyclic-form T. brucei cells to express an endogenous GFP-tagged version of Vps23, the Tsg101 orthologue that anchors the ESCRT-I complex. Affinity purification followed by quantitative mass spectrometry then pulled down the proteins that travel with TbVps23 in living cells, allowing the researchers to confirm predicted partners and uncover unexpected ones.

The most striking biochemical discovery was that trypanosome ESCRT-I is not the canonical heterotetramer familiar from yeast and animals. Instead, the purification identified two novel Vps23-interacting proteins, encoded by adjacent open reading frames Tb927.11.2020 and Tb927.11.2030, that travel stoichiometrically with the core subunits. These proteins are specific to trypanosomes, with no obvious homologues outside the kinetoplastid lineage, and their association with Vps23 indicates that the trypanosome ESCRT-I subcomplex is a heteropentamer. The finding adds a new tier of compositional divergence to a complex long considered structurally conserved, and it underscores how evolutionary flexibility can be woven into even the most fundamental cellular machines.

Equally consequential is the team’s answer to the question of what serves as the trypanosome ESCRT-0 analogue. Rather than a Vps27/STAM pair, which the analyses confirmed is absent from most non-opisthokont lineages, the parasites employ Tom1, a protein carrying the VHS and GAT domains that is broadly distributed across eukaryotes. The researchers demonstrated that trypanosome Tom1, termed TbTom1, colocalises with TbVps23 at endosomal membranes and interacts with a kinetoplastid-specific partner protein the authors nicknamed Jerry, a multi-domain protein studded with three FYVE domains, lipid-binding modules that recognise endosomal phosphoinositides. Together, Tom1 and Jerry appear to fulfil the substrate-recognition role that ESCRT-0 plays in fungi and animals, but through entirely different molecular parts.

Structural predictions reinforced the ancient pedigree of this arrangement. AlphaFold3 modelling of TbTom1 revealed a compact, well-ordered VHS helical bundle linked to a GAT domain, closely superimposable on the VHS domain of human TOM-1, while the remaining regions of the protein are predicted to be intrinsically disordered. This architecture supports the authors’ proposal that Tom1 is the ancestral VHS-GAT-domain-containing cargo adaptor, present in the last common ancestor of eukaryotes and retained across supergroups, whereas the Vps27/Hrs-STAM system of ESCRT-0 is a later innovation restricted to animals and fungi. By mapping the occurrence of Tom1 and Jerry orthologues across the Euglenozoa, the researchers showed that Tom1 is universally retained within the phylum while Jerry is absent from diplonemids, tracing a lineage-specific layer of specialisation on top of a conserved core.

The experimental evidence connecting these proteins to endocytic function came from cellular phenotyping. Cells expressing tagged versions of TbTom1 or TbJerry showed significantly enlarged flagellar pockets, with morphometric analysis of DAPI-stained cells revealing a marked increase in pocket area compared with the parental line, and tagged TbJerry cells additionally displaying a subtle nozzle-like distortion of the pocket. Because the flagellar pocket is the sole site of endocytosis in trypanosomes, such expansion implies a direct perturbation of membrane uptake and trafficking throughput. The phenotypes were measured across individual cloned lines and validated by immunoblotting of endogenous tags, giving the morphological data a firm molecular footing.

Curiously, the machinery appears dispensable for parasite viability in laboratory culture. RNA interference targeting TbTom1 in bloodstream-form cells reduced transcript levels by roughly 65 percent yet left proliferation unimpaired over an eight-day course, and mass spectrometric profiling of the silenced proteome showed that overall protein composition shifted only modestly. Concanavalin A uptake assays, which track soluble cargo from the flagellar pocket through endosomes to the lysosome, proceeded indistinguishably in TbTom1-depleted cells and controls. The authors interpret this resilience as evidence of redundancy or adaptability within the trypanosome sorting network rather than irrelevance of Tom1, a pattern consistent with the plasticity that their comparative analyses document throughout the system.

Broadly, the study reframes how biologists should think about the early ESCRT machinery. Evidence that Tom1 functions within the ESCRT pathway of trypanosomes supplies the fourth eukaryotic supergroup in which such a role has been demonstrated, and the authors argue that Tom1, not Vps27/STAM, is likely part of the pan-eukaryotic early ESCRT apparatus. At the same time, the heteropentameric ESCRT-I complex and the kinetoplastid-restricted Jerry protein illustrate how individual lineages continue to elaborate and customise the machinery, echoing earlier discoveries such as the plant-specific FREE1 adaptor, whose orthologues the team also surveyed across embryophytes. Evolution, in this view, has conserved the skeleton of the sorting system while repeatedly rebuilding its sensory apparatus.

For parasitologists, the implications extend toward intervention. Trypanosomes depend on relentless endocytic turnover of their variant surface glycoproteins and invariant surface receptors to evade the immune system, and any component that is parasite-specific, such as the novel ESCRT-I subunits or Jerry, represents a potential Achilles heel that host proteins do not share. Conversely, the conserved Tom1-dependent pathway offers a benchmark against which the animal and fungal systems can be reinterpreted, potentially correcting an animal-centric bias that has coloured membrane trafficking research for decades. What this study makes clear is that the deepest lessons about how eukaryotic cells move their membranes may come not from yeast or human tissue culture, but from an ancient parasite whose cellular geography forces every molecular handoff to happen in one remarkable pocket of membrane.

Subject of Research: The composition and evolution of the ESCRT endosomal sorting system in trypanosome parasites

Article Title: The trypanosome ESCRT system possesses both novel components and under-recognised pan-eukaryotic features

Article References: Padilla-Mejia, N. E., Durante, I. M., Záhonová, K., Stříbrná, E., Heller, J., Dacks, J. B., Lukeš, J., & Field, M. C. (2026). The trypanosome ESCRT system possesses both novel components and under-recognised pan-eukaryotic features. BMC Biology. https://doi.org/10.1186/s12915-026-02730-4

Image Credits: AI Generated

DOI: 10.1186/s12915-026-02730-4

Keywords: ESCRT, endocytosis, trypanosomes, Trypanosoma brucei, Tom1, Vps23, flagellar pocket, protein trafficking, endosomes, eukaryotic evolution, VHS domain, FYVE domain